Summit Therapeutics PLC (LON:SUMM) insider Leopoldo Zambeletti sold 11,358 shares of the business’s stock in a transaction that occurred on Wednesday, October 24th. The shares were sold at an average price of GBX 28 ($0.37), for a total transaction of £3,180.24 ($4,155.55).
SUMM remained flat at $GBX 24 ($0.31) during trading on Friday. 24,511 shares of the company’s stock traded hands, compared to its average volume of 34,608. Summit Therapeutics PLC has a 12 month low of GBX 140 ($1.83) and a 12 month high of GBX 269.70 ($3.52).
ILLEGAL ACTIVITY NOTICE: This story was originally posted by Equities Focus and is owned by of Equities Focus. If you are viewing this story on another domain, it was copied illegally and republished in violation of U.S. & international copyright & trademark legislation. The original version of this story can be viewed at https://www.equitiesfocus.com/2018/11/10/summit-therapeutics-plc-summ-insider-leopoldo-zambeletti-sells-11358-shares.html.
About Summit Therapeutics
Summit Therapeutics plc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of novel medicines to treat rare and infectious diseases in the United Kingdom and North America. It is conducting clinical programmes focused on the genetic disease Duchenne muscular dystrophy (DMD) and the infectious disease Clostridium difficile infection (CDI).
Featured Story: What Does Beta Mean In Stock Selection
Receive News & Ratings for Summit Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Summit Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.